The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2

被引:4
|
作者
Kraay, A. N. M. [1 ,2 ]
Gallagher, M. E. [3 ]
Ge, Y. [4 ]
Han, P. [5 ]
Baker, J. M. [5 ]
Koelle, K. [6 ]
Handel, A. [7 ,8 ]
Lopman, B. A. [5 ]
机构
[1] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61820 USA
[2] Univ Illinois, Inst Genom Biol, Urbana, IL 61801 USA
[3] Johns Hopkins Univ Appl Phys Lab, Laurel, MD USA
[4] Univ Southern Mississippi, Sch Hlth Profess Publ Hlth, Hattiesburg, MS USA
[5] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA USA
[6] Emory Univ, Dept Biol, Atlanta, GA USA
[7] Univ Georgia, Dept Epidemiol & Biostat, Athens, GA USA
[8] Univ Georgia, Ctr Ecol Infect Dis, Athens, GA USA
关键词
booster; evolution; vaccination; COVID-19; non-pharmaceutical interventions; INFECTION;
D O I
10.1098/rsif.2022.0477
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Periodic resurgences of COVID-19 in the coming years can be expected, while public health interventions may be able to reduce their intensity. We used a transmission model to assess how the use of booster doses and non-pharmaceutical interventions (NPIs) amid ongoing pathogen evolution might influence future transmission waves. We find that incidence is likely to increase as NPIs relax, with a second seasonally driven surge expected in autumn 2022. However, booster doses can greatly reduce the intensity of both waves and reduce cumulative deaths by 20% between 7 January 2022 and 7 January 2023. Reintroducing NPIs during the autumn as incidence begins to increase again could also be impactful. Combining boosters and NPIs results in a 30% decrease in cumulative deaths, with potential for greater impacts if variant-adapted boosters are used. Reintroducing these NPIs in autumn 2022 as transmission rates increase provides similar benefits to sustaining NPIs indefinitely (307 000 deaths with indefinite NPIs and boosters compared with 304 000 deaths with transient NPIs and boosters). If novel variants with increased transmissibility or immune escape emerge, deaths will be higher, but vaccination and NPIs are expected to remain effective tools to decrease both cumulative and peak health system burden, providing proportionally similar relative impacts.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] The societal value of SARS-CoV-2 booster vaccination in Indonesia
    Johnson, Rob
    Djaafara, Bimandra
    Haw, David
    Doohan, Patrick
    Forchini, Giovanni
    Pianella, Matteo
    Ferguson, Neil
    Smith, Peter C.
    Hauck, Katharina D.
    VACCINE, 2023, 41 (11) : 1885 - 1891
  • [2] Booster Vaccination to Reduce SARS-CoV-2 Transmission and Infection
    Wald, Anna
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (04): : 327 - 328
  • [3] Role of anti-Spike SARS-CoV-2 IgG antibodies in protection from SARS-CoV-2 Infection after booster vaccination
    Senn, A.
    Brueckner-Fracowiak, J.
    Kostyra, J.
    Biedermann, S.
    Fux, A.
    Bach, A.
    Schuster, M.
    Baurmann, H.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2023, 53 : 363 - 363
  • [4] Booster anti SARS-COV-2 vaccination acts more on elderly
    Patella, V.
    Zunno, R.
    Pierro, L.
    Latempa, M.
    Giuliano, A.
    Grande, G.
    ALLERGY, 2023, 78
  • [5] Booster vaccination with mRNA vaccines against SARS-CoV-2 virus
    Pecks, Ulrich
    Schleussner, Ekkehard
    Zollkau, Janine
    Scharl, Anton
    Kehl, Sven
    Hagenbeck, Carsten
    Schlembach, Dietmar
    Abou-Dakn, Michael
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (02) : 130 - 130
  • [6] SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination
    Monin, Malte Benedikt
    Baier, Leona
    Berger, Moritz
    Gorny, Jens Gabriel
    Zhou, Taotao
    Mahn, Robert
    Sadeghlar, Farsaneh
    Moehring, Christian
    van Bremen, Kathrin
    Boesecke, Christoph
    Rockstroh, Jurgen
    Strassburg, Christian
    Eis-Huebinger, Anna-Maria
    Gonzalez-Carmona, Maria Agnes
    GUT, 2023, 72 (06) : 1227 - 1229
  • [7] Ongoing global and regional adaptive evolution of SARS-CoV-2
    Rochman, Nash D.
    Wolf, Yuri I.
    Faure, Guilhem
    Mutz, Pascal
    Zhang, Feng
    V. Koonin, Eugene
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (29)
  • [8] The ongoing evolution of UShER during the SARS-CoV-2 pandemic
    Hinrichs, Angie
    Ye, Cheng
    Turakhia, Yatish
    Corbett-Detig, Russell
    NATURE GENETICS, 2024, 56 (01) : 4 - 7
  • [9] The ongoing evolution of UShER during the SARS-CoV-2 pandemic
    Angie Hinrichs
    Cheng Ye
    Yatish Turakhia
    Russell Corbett-Detig
    Nature Genetics, 2024, 56 : 4 - 7
  • [10] SARS-CoV-2 one year on: evidence for ongoing viral adaptation
    Peacock, Thomas P.
    Penrice-Randal, Rebekah
    Hiscox, Julian A.
    Barclay, Wendy S.
    JOURNAL OF GENERAL VIROLOGY, 2021, 102 (04):